These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37702920)

  • 1. Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19.
    Satram S; Ghafoori P; Reyes CM; Keeley TJH; Birch HJ; Brintziki D; Aldinger M; Alexander E; Lopuski A; Sarkis EH; Gupta A; Shapiro AE; Powers JH
    J Patient Rep Outcomes; 2023 Sep; 7(1):92. PubMed ID: 37702920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Rodrigues Falci D; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Parra S; Sager JE; Austin D; Peppercorn A; Alexander E; Yeh WW; Brinson C; Aldinger M; Shapiro AE;
    JAMA; 2022 Apr; 327(13):1236-1246. PubMed ID: 35285853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
    Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Falci DR; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Hebner CM; Sager J; Mogalian E; Tipple C; Peppercorn A; Alexander E; Pang PS; Free A; Brinson C; Aldinger M; Shapiro AE;
    N Engl J Med; 2021 Nov; 385(21):1941-1950. PubMed ID: 34706189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Within-trial economic analysis of resource use from COMET-ICE: A phase 3 clinical trial evaluating sotrovimab for the treatment of patients with COVID-19 at high risk of progression.
    Lokhandwala T; Acharya M; Farrelly E; Coutinho AD; Bell CF; Svedsater H
    J Manag Care Spec Pharm; 2022 Nov; 28(11):1261-1271. PubMed ID: 36282931
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
    ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group
    Lancet Infect Dis; 2022 May; 22(5):622-635. PubMed ID: 34953520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing health-related quality of life and identifying disease predictors among patients suspected of having long COVID: an analysis of COMET-ICE clinical trial data.
    Gelhorn HL; Ghafoori P; Cutts K; Birch H; Savva Y; Satram S; Lloyd E; Chen WH
    Front Public Health; 2024; 12():1278106. PubMed ID: 38784592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C).
    Bell CF; Bobbili P; Desai R; Gibbons DC; Drysdale M; DerSarkissian M; Patel V; Birch HJ; Lloyd EJ; Zhang A; Duh MS;
    Clin Drug Investig; 2024 Mar; 44(3):183-198. PubMed ID: 38379107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers.
    Nader A; Alexander E; Brintziki D; Haggag AZ; Harrison SA; Hawes IA; Hezareh M; Lippa AM; Okamasa A; Okour M; Okuda N; Sager JE; Segal S; Shida Y; Skingsley A; Williams R; Yoon EY; Austin D
    Clin Pharmacokinet; 2024 Jan; 63(1):57-68. PubMed ID: 37955825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
    JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance analysis following sotrovimab treatment in participants with COVID-19 during the phase III COMET-ICE study.
    Subramanian S; Schnell G; Iulio JD; Gupta AK; Shapiro AE; Sarkis EH; Lopuski A; Peppercorn A; Aldinger M; Hebner CM; Cathcart AL
    Future Virol; 2023 Nov; ():. PubMed ID: 38074312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes of Sotrovimab Treatment in 10 High-Risk Patients with Mild COVID-19: A Case Series.
    Takeda K; Kasai H; Sakao S; Saito M; Shikano K; Naito A; Abe M; Kawasaki T; Yahaba M; Taniguchi T; Igari H; Suzuki T
    Am J Case Rep; 2022 Jul; 23():e936832. PubMed ID: 35802524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Content validity and psychometric properties of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus
    Keeley TJH; Satram S; Ghafoori P; Reyes C; Birch HJ; Raymond K; Gelhorn HL; Kosinski M; Saucier CD; Mitchell Foster A; Lopuski A; Powers JH
    Qual Life Res; 2023 Jun; 32(6):1645-1657. PubMed ID: 36703019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.